Related Experiment Video
Updated: Jun 7, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Identifying and validating biomarkers for Alzheimer's disease
1Laboratory of Psychiatry and Experimental Alzheimer's Research, Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria. christian.humpel@i-med.ac.at
Trends in Biotechnology
|October 26, 2010
Summary
Diagnosing Alzheimer's disease (AD) requires validated biomarkers. Future AD diagnosis will likely rely on combined analysis of multiple biomarkers from cerebrospinal fluid (CSF) and blood.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Diagnostics
Background:
- Accurate Alzheimer's disease (AD) diagnosis is crucial for effective management.
- Current gold standard involves measuring specific proteins in cerebrospinal fluid (CSF).
- Limitations exist in current diagnostic methods and biomarker discovery.
Purpose of the Study:
- To highlight the importance of identifying and validating novel biomarkers for AD diagnosis.
- To discuss challenges in discovering and implementing new biomarkers.
- To propose future directions for AD diagnostics.
Main Methods:
- Review of current ELISA-based biomarker measurements (Aβ42, tau, p-tau181).
- Exploration of advanced techniques like microarrays and mass spectrometry for novel biomarker discovery.
- Emphasis on optimizing sample handling and bioinformatics interpretation.
Main Results:
- ELISA for CSF Aβ42, total tau, and p-tau181 is the established method for probable AD.
- Significant challenges remain in discovering new biomarkers in CSF and blood.
- Bioinformatics and optimized sample handling are critical for biomarker validation.
Conclusions:
- Future Alzheimer's disease diagnosis will likely involve a multi-biomarker approach.
- A patient-specific signature combining several biomarkers is anticipated.
- Continued research into novel biomarkers and analytical methods is essential.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...